MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors its latest Company Update presentation ahead of a comprehensive roadshow to investment institutions, analysts and shareholders in the United States, where interim-CEO Dr. Jerry Kanellos will be updating on recent trials progress and upcoming milestones.
Dr. Kanellos will be meeting with key US fund managers to highlight the current position and strength of Immuron’s patent portfolio, the Company’s multiple clinical trials which are underway in the areas of NASH, ASH, C Clostridium Difficile Infection, and the increasing traction Immuron’s Travelan product, for the prevention of travellers’ diarrhea, is gaining in both the Australian and US market.
Immuron’s newly appointed Interim-CEO Dr. Jerry Kanellos highlighted;
“We have some very exciting times ahead at Immuron as many of our projects approach critical milestones and targets. Following the initial share price fluctuations after our NASDAQ listing, it’s important than we now firm up our investor base and showcase Immuron’s amazing technology platform to those who are yet to see and understand the Immuron story.
I’m truly honored to be able to present Immuron to the market and explain the Company value proposition to US institutional investors as we move into the next phase of our lifecycle.”
A copy of the roadshow presentation is available by clicking on the following link:
Immuron Ltd (ASX:IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: http://www.immuron.com
Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.
CONTACT: COMPANY CONTACT: Dr. Jerry Kanellos Interim-Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 firstname.lastname@example.org US INVESTORS RELATIONS: Jon Cunningham RedChip Companies, Inc. US Ph: +1 (407) 644 4256, (ext. 107) email@example.com AUSTRALIA INVESTORS RELATIONS: Peter Taylor NWR Communications AUS Ph: +61 (0)4 1203 6231 firstname.lastname@example.org US PUBLIC RELATIONS: Eric Fischgrund FischTank - Marketing and PR US Ph: +1 (646) 699 1148 email@example.com
News Provided by GlobeNewswire
© 2017 GlobeNewswire, Inc. All Rights Reserved